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C-reactive protein (CRP) is a prototypic human acute phase reactant composed of five identical subunits. Emerging evidence in-
dicates that CRP is not merely a predictor of cardiovascular disease, but may also be a direct mediator. However, the diverse and 
sometimes contradictory activities of CRP have considerably hampered the attempts to define the exact role of CRP in atherogen-
esis. Here, we review the multiple layers of regulation of CRP’s structure and function, highlighting how local inflammation con-
ditions, such as the abundance of damaged cell membranes and redox homeostasis, can tip the balance of the pro- and anti-   
inflammatory activities of CRP. We propose that the highly controlled interplay between different structural conformations of 
CRP underlies its intrinsic property as a fine modulator of inflammation and atherogenesis. 
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C-reactive protein (CRP) is an ancient protein that has been 
highly conserved throughout evolution [1,2]. No deficiency 
or coding sequence mutation of CRP has yet been identified 
in humans, implying that there are important biological 
functions for CRP. CRP is composed of five identical sub- 
units that are non-covalently associated with each other 
(Figure 1). The two opposite faces of the disc-like structure 
of CRP present distinct binding sites for interaction with 
other molecules. Through the recognition face, CRP binds a 
panel of endogenous and exogenous ligands found on dam-
aged cell membranes, bacterial cell walls, polysaccharides 
and chromatin. Ligand-bound CRP can further interact with 
C1q via its effector face to activate the classical comple-
ment pathway (CCP). Therefore, CRP is considered to act 
as a pattern recognition receptor in innate immunity, facili-
tating the efficient clearance of harmful materials [3]. 
Moreover, the effector face of CRP appears to also possess 
binding sites for cell surface receptors, including FcγR [4,5],   
Figure 1  The X-ray crystal structure of CRP in complex with phospho-
choline. Five subunits associate with each other non-covalently into a 
disc-like structure with a diameter of ~10 nm. 
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FcαR [6], SR-A [7] and LOX-1 [8], thus giving CRP the 
potential to modulate the responses of immune and vascular 
cells. These characteristics lead to the consensus that CRP is 
an important component of the host defense and inflamma-
tion [1–3], despite the fact that the actual function of CRP 
remains to be clearly defined in an appropriate animal mod-
el [1,9,10]. 
CRP is a typical human acute phase reactant that is pri-
marily secreted by the liver [1]. The serum concentration of 
CRP can rise more than 1000-fold in response to tissue in-
jury or infection and returns to a baseline level of less than 1 
µg/mL upon recovery of homeostasis. The tight correlation 
between the level of CRP and the severity of inflammation 
forms the basis for the broad classification of this protein as 
a non-specific marker of inflammation [1]. Although a con-
centration of CRP less than 10 µg/mL was originally con-
sidered to be clinically insignificant, accumulating evidence 
indicates that such a subtle elevation can be a sensitive pre-
dictor for the future risk of cardiovascular disease (CVD) in 
apparently healthy populations [11]. Despite considerable 
debates on the prediction strength [12] and causality [13] of 
elevated CRP levels, CRP has nonetheless gained the fame 
as an independent marker of CVD which may be used in the 
screening of high-risk individuals for primary intervention 
[14] or to evaluate the effectiveness of a specific treatment 
[15]. Furthermore, data from numerous reports describing 
the pro-inflammatory activities of CRP on vascular and cir-
culating cells support the idea that CRP could also be a po-
tential drug target for treating CVD [9,16]. These results 
fuel the enthusiasm for additional research but yield intense 
controversies as well. We will discuss these issues in the 
following sections. 
1  The controversial role of CRP in  
atherosclerosis 
CVD is the leading cause of death and disability worldwide. 
Over 17 million people died from CVD in 2008; this num-
ber will increase to 23.6 million by 2030 as estimated by 
WHO. Fortunately, timely intervention can effectively re-
duce the mortality and morbidity of CVD, which accounts 
for 4% and 42% of the premature deaths in high- and low- 
income countries, respectively. Such preventability of CVD 
highlights the importance of diagnosis before onset or in the 
early stages of the disease. Although the level of plasma 
cholesterol has been established as the most sensitive risk 
factor for CVD, nearly half of all CVD events occur in in-
dividuals with normal or low plasma cholesterol levels. 
Thus, it is mandatory to improve the current methods of 
assessing CVD risk. Because inflammation plays a critical 
role in all stages of atherosclerosis [17,18], the primary 
cause of CVD, the possibility exists that inflammation 
markers may also correlate with CVD progression. As the 
most widely used marker of inflammation in clinical prac-
tice, CRP has received intense interest and has proved to be 
a strong predictor of CVD independent of and complemen-
tary to plasma cholesterol levels [11,14]. Moreover, the 
availability of cheap, sensitive and standardized assays to 
measure CRP levels allows the inclusion of CRP evaluation 
in current methods of risk assessment and diagnosis of CVD 
as a reasonably cost-effective choice. 
In a recent large-scale clinical investigation known as 
JUPITER, statin treatment reduced 5-year CVD events by 
50% in apparently healthy individuals with high CRP levels 
but normal cholesterol levels [14]. This provides the first 
proof that early intervention of CVD can be effectively 
guided by CRP levels alone and suggests that the current 
methods of risk assessment will be improved by the inclu-
sion of CRP evaluation. Interestingly, evidence has shown 
that changes in plaque size and the risk of recurrent events 
after a treatment are closely correlated with alterations in 
CRP levels [15,19]. Such a tight association between CRP 
levels and progression of the disease implies that CRP is not 
simply a sensitive marker but a direct mediator of CVD. 
Indeed, CRP can be detected in early lesions of atheroscle-
rosis in humans [20] and its staining intensity correlates 
with disease development [21]. Moreover, CRP co-localizes 
with atherogenic mediators, including modified low density 
lipoproteins (LDL) [22,23], activated complement [24] and 
foam cells [20]. Together with the reported pro-inflamma- 
tory actions of CRP [25,26], including activation of com-
plement and stimulation of expression of cytokines and ad-
hesion molecules in endothelial cells, this protein is emerg-
ing as a promising drug target for CVD treatment [16]. Ac-
cordingly, a small molecule inhibitor that blocks the ligand 
binding site on CRP significantly reduced the comple-
ment-dependent infarction size in a rat model [27]. 
Despite the aforementioned compelling supportive evi-
dence, there is also remarkable evidence that negates the 
role of CRP as a specific marker and a mediator of CVD. 
For example, several epidemiological studies failed to find 
an independent correlation between CRP and the disease 
[28–30]. A causal involvement of CRP in CVD was recent-
ly rejected by the finding that polymorphisms in non-coding 
nucleotides of the CRP gene affects the basal plasma levels 
of CRP but does not correlate with the risk of future CVD 
events [13]. Moreover, transgenic expression of human 
CRP or knock-out of endogenous CRP in atherosclerosis- 
prone mice has been reported to accelerate [31], show no 
effect [32] or even protect against the development of ath-
erosclerosis [33,34]. Knock-in of human CRP in rabbits, on 
the other hand, appeared to reduce the lesion formation, 
albeit with no statistical significance [35]. Even worse is 
that in vitro studies frequently generate conflicting results 
[36–45] and some of the reported activities of CRP have 
been ascribed to impurities such as azide or endotoxin 
[39,46,47]. The acute-phase reactant nature of CRP adds an 
additional layer of complexity: how does a protein with two 
to three orders of dynamic fluctuation in its plasma levels 
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function as a fine modulator of sophisticated cellular or 
physiological systems [1]?  
2  The bioactivities of CRP are dependent on 
conformational states 
These enigmas may be addressed by regulated changes in 
the conformation and activity of CRP that occur during lo-
cal inflammation [48–53]. The pentameric assembly of CRP 
can be disrupted to form separated subunits that are termed 
monomeric CRP (mCRP) [48–53]. “mCRP” is also used as 
the abbreviation for “modified CRP” because the conver-
sion to mCRP is usually accompanied by significant altera-
tions in the native subunit structure and epitope expression. 
Accordingly, a significant loss of secondary structural ele-
ments and a marked relaxation of the tertiary packing have 
been demonstrated upon dissociation of CRP to mCRP 
[54–56]. Presumably due to the prominent conformation 
rearrangement, mCRP is unable to spontaneously re-asso- 
ciate back to the cyclic pentameric CRP [57]; rather, this 
molecule is prone to aggregating into high-order oligomers 
composed of tens of monomers [58]. Therefore, the propen-
sity of self-assembly and the relative disordered/flexible 
conformation of mCRP, on the one hand, hinder the deter-
mination of its high-resolution structure by X-ray crystal-
lography or NMR; while on the other hand are likely to 
confer mCRP enhanced bioactivities and new functionalities 
by presenting clusters of functional sites and by releasing 
critical motifs that are not accessible in the structure of 
CRP. 
Indeed, conversion to mCRP greatly augmented the ca-
pacity of CRP to interact with various ligands and to regu-
late complement activation. We have shown that mCRP 
binds avidly to native and modified LDL, to which CRP 
exhibits low-to-moderate binding [59]. Moreover, we found 
that mCRP interacted with C1q in both the free and bound 
states, in contrast to CRP, which recruits C1q only when 
complexed with multivalent ligands [60]. As such, mCRP 
can either inhibit or activate the CCP depending on whether 
it is surface-bound. Since mCRP (but not CRP) also binds 
to Factor H, the activation of CCP by mCRP is largely re-
stricted to the opsonic C3 level without proceeding to the 
more inflammatory C5 stage [60]. Subsequent studies con-
firmed the enhanced interactions of mCRP with modified 
lipoproteins [61] and complement [62–67] and further re-
vealed the important contributions of mCRP in promoting 
non-inflammatory clearance of apoptotic or necrotic cells 
by controlling complement activation on the cell surface 
through balanced recruitment of C1q, Factor H and C4bp 
[64–66]. Because inappropriate handling of CRP, including 
lyophilization [68], storage in the absence of calcium [69] 
and immobilization onto microtiter wells [60,70], leads to 
the disruption of the pentameric structure, the reported 
properties of CRP suffering these technical pitfalls should 
be re-evaluated with Factor H interaction as a prominent 
example [60,64,71]. 
3  Dissociation of CRP localizes the enhanced 
bioactivities 
The significantly enhanced bioactivities of mCRP suggest 
that mCRP is an activated isoform while CRP is in a basal 
state. This hypothesis thus implicates the dissociation of 
CRP as a key mechanism that acts as a firewall to avoid 
fluctuations in the serum levels of CRP to generate immedi-
ate global effects. However, the concept of mCRP has been 
disputed for decades since its first demonstration by Po-
tempa et al. [54] in the early 1980s. The major concern is 
that the structure of the CRP molecule is exceptionally sta-
ble in the presence of calcium [1] and the preparation of 
mCRP requires highly denaturing treatments of CRP with 
concomitant chelation of calcium [54]. Therefore, the iden-
tification of dissociation pathways with a pathophysiologi-
cal relevance is of paramount importance. The first hint 
came from the open-ring-like appearance of CRP bound to 
lipid monolayers when visualized by electron microscopy, 
arguing for a membrane-induced dissociation [72]. With 
this observation, we have provided compelling evidence 
that the lysoPC-dependent, multi-point binding of CRP to 
model or apoptotic cell membranes can overcome the stabi-
lization effects of calcium and induce a rapid formation of a 
hybrid state [73]. This hybrid state, in the form of a sepa-
rated subunit with near-native conformation, is termed 
mCRPm and eventually gives rise to mCRP with the aid of 
the relatively hydrophobic and fluidic characteristics of 
membranes [73]. 
The five subunits in CRP, in principle, provide multiple 
binding sites in one molecule. This is of particular im-
portance for the effectors and receptors of CRP whose acti-
vation usually requires clustering or multi-point attachment. 
Among those, C1q, a hexameric protein, is an outstanding 
representative. At least two of the C1q subunits need to be 
in a bound state in order for C1q to be activated, resulting in 
initiation of the CCP. Since the relatively small size of CRP 
(~10 nm in diameter) allows it to bind only one C1q subunit, 
this leads to the idea that close packing on the surface is the 
prerequisite for CRP to activate the complement pathway 
[74]. As such, the low expression level of CRP under nor-
mal physiological conditions and during the early phases of 
inflammation would restrict its major contribution to the 
late stages of tissue injury or infection. This appears to be 
incompatible with the proposed function of CRP in the 
non-inflammatory clearance of apoptotic cells in times of 
health and disease [75] and its role as a component in the 
innate immunity and host defense [1,3]. In this regard, the 
rapid formation of mCRPm can override the size limitation 
such that even the dissociation of a single CRP molecule 
can provide multi-point binding to, for example, activate 
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C1q. Therefore, the damaged membrane-induced stepwise 
dissociation of CRP can represent an efficient mechanism 
for prompt amplification of the bioactivities locally on 
membranes, as evidenced by the significantly enhanced 
CCP activation by mCRPm [73]. 
Due to the reduced binding affinity associated with the 
loss of multi-point attachment as the result of monomeriza-
tion, mCRPm can detach from the membrane and undergo 
further conformational changes leading to the generation of 
extracellular mCRP [73], which may later reassociate with 
the membrane by direct insertion. Alternatively, analogous 
to the dissociation of CRP induced by immobilization onto 
plastic surfaces, the mild hydrophobicity of damaged mem-
branes can also facilitate structural rearrangements in 
mCRPm for direct conversion to membrane-associated 
mCRP. However, considering the relatively slow dynamics 
of the conversion process, the significant accumulation and 
effective actions of mCRP mostly likely occur in inflam-
matory loci where injured cells and damaged membranes 
are enriched. This has led us to propose that the dissociation 
of the CRP molecule is an activating mechanism that is re-
quired for the expression of enhanced bioactivities and is 
also a buffering mechanism that localizes the actions of 
mCRP into inflammatory loci to prevent the possible global 
effects directly induced by large-scale alterations in the se-
rum levels of CRP [73]. Consistent with our proposal, im-
munohistochemical analyses using highly specific antibod-
ies revealed that mCRP, not CRP, was the major isoform 
present in local lesions, including atherosclerotic plaques 
[55,76], diabetic kidneys [77] and stroke neovessels [78]. 
The proposal of disturbed membranes being the major 
sites for mCRP generation has been further corroborated by 
elegant studies that demonstrate the binding and dissocia-
tion of CRP on the surface of necrotic cells [65,66] and ac-
tivated platelets [76,79] in a lysoPC-dependent manner [76]. 
Moreover, Dr. Peter and colleagues [80] recently identified 
novel pathways for mCRP generation upon binding of CRP 
to amyloid aggregates, the typical pathological feature 
found in brains of persons with Alzheimer’s disease, and 
lysoPC-enriched microparticles released by activated cells 
or isolated from blood of patients with myocardial infarc-
tion [81]. As disturbed membranes, these newly identified 
inducers also present multi-point binding sites and relative 
hydrophobicity, factors critical for driving the conversion of 
CRP to mCRP [73]. An additional factor, high membrane 
curvature, has recently been revealed by showing that CRP 
preferentially binds and dissociates on lipid-coated nano-
particles smaller than 28 nm [82]. This is likely due to the 
less dense packing of lipid head-groups in the context of 
nanoparticles that lack stuffing lipids (e.g., cholesterol) and 
proteins found in biological membranes, which would in-
crease the accessibility of PC ligands for easier binding of 
CRP, and due to the stronger tension imposed to facilitate 
dissociation when more than one subunit in a single pen-
tamer is bound by the particle. However, further reduction 
of the particle size to below 20 nm appeared to be unfavor-
able for CRP dissociation [59], which may relate to the dif-
ficulty in multi-point binding of CRP to smaller particles. 
All of the dissociation pathways of CRP identified thus 
far are primarily associated with local inflammatory condi-
tions, such as damaged membranes [65,66,73,76,79], 
pathological protein aggregates [80] and microparticles re-
leased by activated cells [81]. Interestingly, the acidic pH 
frequently found in inflamed tissues can also boost the 
binding capacity of CRP even in the absence of pentamer 
dissociation [83]; however, after binding to immobilized 
ligands at a low pH, a prominent exposure of the mCRP 
epitope has been observed [83]. These results further sup-
port the idea that interactions of CRP with the inflammatory 
microenvironment are critical for the expression of en-
hanced bioactivities. In addition to the localized dissociation 
of CRP, direct synthesis by activated macrophag-
es/monocytes likely provides another source of mCRP [84]. 
As such, CRP may primarily serve as a systemic inflamma-
tion marker, while mCRP is the active player in local in-
flammation. Nonetheless, if locally formed mCRP could be 
released into circulation, it might serve as a better marker 
for the underlying inflammatory process than CRP. Ac-
cordingly, mCRP has been detected on circulating micro-
particles [81] and the discovery of RNA aptamers specifi-
cally recognizing mCRP [85] may eventually result in the 
development of clinical assays for mCRP. Alternatively, 
autoantibodies against mCRP that were found to be corre-
lated with autoimmune [86–88] and heart diseases [89] 
could be regarded as an indirect index to measure global 
mCRP production. 
4  Redox regulation of bioactivities of mono-
meric CRP 
The actions of mCRP in various aspects of inflammation are 
emerging; however, the mechanism by which the potent 
activities of mCRP are regulated remains poorly defined. 
By careful examination of the sequence of human CRP, we 
found that there are two cysteines (i.e., Cys36 and Cys97) 
that form an intra-subunit disulfide bond. Their evolutionary 
conservation strongly suggests that these cysteines are es-
sential for the structure and function of CRP. We further 
showed that this intra-subunit disulfide bond could be re-
duced only in mCRP but not in CRP. This pattern of reduc-
tion indicates that the dissociation of CRP is the prerequisite 
for the disulfide bond to be modulated by the environmental 
redox status. In addition to physiological small reducing 
agents, thioredoxin, a ubiquitous reducing enzyme that is 
critical for thiol/disulfide redox homeostasis [90,91], was 
also found to reduce mCRP levels with high efficiency. In-
deed, the frequent co-localization of thioredoxin and mCRP 
in advanced plaques indicates that the reduction of mCRP 
could occur in local inflammation. After reduction, mCRP 
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showed moderately enhanced capacity to activate the CCP 
and significantly enhanced capacity to induce pro-inflam- 
matory responses on endothelial cells (EC) in rabbit aorta 
and in mice. Comparable results were obtained with 
Cys-mutated mCRP, in which the two cysteines were mu-
tated to alanines. These findings thus indicate the in-
tra-subunit disulfide bond as an important switch modulat-
ing the activities of mCRP [55]. 
Although FcγRIII has been reported to be the putative 
receptor for mCRP on neutrophils [56], we failed to find 
any impact of this receptor on EC binding and activation of 
Cys-mutated mCRP. By using a combination of experi-
mental techniques, we have demonstrated that Cys-mutated 
mCRP interacts with model and EC membranes by direct 
insertion into the cholesterol-enriched lipid raft micro-  
domains [92]. Moreover, disruption of lipid rafts by MβCD 
or nystatin eliminated the stimulation effects of Cys-   
mutated mCRP on EC and in rabbit vessels. Accordingly, 
we identified a cholesterol binding motif (CBM; a.a. 35–47) 
containing Cys36 in the sequence of human CRP which has 
been conserved throughout evolution. Indeed, reduction or 
mutating cysteines promoted the interactions of Cys-   
mutated or reduced mCRP with both model and cell mem-
branes. In addition, the specific antibody 8C10 against the 
epitope containing the CBM markedly repressed lipid raft 
insertion of Cys-mutated mCRP. These lines of evidence 
thus identify lipid rafts as the major cellular sensors of re-
duced mCRP [92] and reveal that the unlocking of CBM in 
mCRP after reduction underlies the enhanced capacity of 
reduced mCRP to interact with lipid rafts and to stimulate 
cellular responses [55]. Interestingly, rabbit mCRP also 
showed enhanced capacity to activate EC after reduction 
[55]. This observation provides evidence that cholesterol 
binding and redox regulation of mCRP are functionally 
conserved. 
Lipid rafts are specialized signaling platforms in the 
plasma membrane [93]. Hence, interacting with lipid rafts 
confers mCRP unique advantages to access to various sig-
naling components. For example, integration into a lipid raft 
may enable mCRP to interact with transmembrane segments 
of membrane proteins that are inaccessible from the extra-
cellular space. Moreover, membrane insertion-induced 
conformation changes in mCRP, which may not be the same 
for reduced and non-reduced counterparts, likely create ad-
ditional binding specificities for surrounding receptors. As 
such, mCRP could further act as a scaffolding protein due to 
its polymeric assembly, triggering distinct downstream 
pathways under different conditions by organizing diverse 
sets of co-factors. Accordingly, disruption of lipid rafts has 
recently been shown to reverse the effects of mCRP in 
promoting monocyte adhesion to fibrinogen [76] and in 
augmenting fibrin clot formation on EC [94]. Since the lipid 
raft insertion and cell stimulating capacities of mCRP are 
affected by the redox state, care should be taken to control 
the experimental conditions, including the use of wild-type 
or Cys-mutated mCRP, the prevalence of lipid rafts in cer-
tain cell types, and the contents of reducing agents in cell 
culture media. In addition, our unpublished results indicate 
that freshly prepared wild-type mCRP, membrane-associ- 
ated mCRP/mCRPm and spontaneously dissociated mCRP 
in solution-phase are more prone to reduction. 
5  Concluding remarks 
Taken together, we can form a revised cascading model 
demonstrating how the controlled interplay between differ-
ent CRP isoforms can contribute to the development of 
CVD (Figure 2). There are at least three distinct structural 
and functional states of CRP: CRP, mCRP and reduced  
 
 
Figure 2  A cascading model for the function and regulation of CRP isoforms in cardiovascular disease. 
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mCRP. CRP produced by the liver appears to primarily 
serve as a systemic inflammation marker with some anti- 
inflammatory activities [53]. In inflammatory loci, CRP 
molecules either synthesized by local extra-hepatic cells  
[95–99] or entered into these loci from circulation can dis-
sociate into mCRP with the aid of damaged cell membranes 
and acidic stresses. mCRP may mainly act as a pattern 
recognition molecule to facilitate the mobilization of the 
innate immunity and the clearance of damaged materials. 
mCRP can be further reduced to express the enhanced cell 
stimulating capacity. Although the reduction of mCRP in 
the oxidative inflammatory loci seems to be paradoxical, it 
is worth noting that extracellular thioredoxin is up-regulated 
in atherosclerotic plaques [100] and is an emerging marker 
of inflammation [90,101]. Moreover, the generation of 
mCRP on membranes favors local accumulation of mCRP 
and its subsequent reduction by secreted and/or mem-
brane-associated thioredoxin [102] or other reductases, 
thereby allowing reduced mCRP to be functional in situ. 
The potent activities of reduced mCRP could be negatively 
regulated tiple by auto-oxidation of the disulfide bond and 
proteolysis. Interestingly, the degraded CRP fragments are 
also biologically active [103]. 
This model highlights the complexity of CRP regulation 
and raises the concern that the interpretation of the role of 
CRP in CVD should take into account the highly con-
text-dependent interplay between the different structural 
states of CRP isoforms. Indeed, dissociation of CRP into 
mCRP significantly enhances the ligand interaction capacity. 
Irrespective to its redox state, mCRP can regulate LDL me-
tabolism [59,104] and opsonic activation of the complement 
pathway [60], likely exerting atheroprotective actions, in 
particular during the initial stages of atherogenesis [105] by 
promoting the clearance of the damaged material. Further 
reduction of the intra-subunit disulfide bond in mCRP un-
locks the CBM, thereby unmasking pro-inflammatory activ-
ities, which may accelerate disease progression and trigger 
acute events. This result is also the first demonstration of a 
sulfur switch (i.e., Cys36), an essential component of redox 
regulation [106], in an acute phase reactant, expressing an 
“on” state in the reduced form. Such a cascading mecha-
nism would ensure prompt and localized responses and de-
termine the expression of anti- or pro-inflammatory activi-
ties of CRP, mCRP and reduced mCRP during inflamma-
tion. As such, these multiple layers of regulation underlie 
the intrinsic competence of CRP as a fine modulator of in-
flammation through sequential conformational changes. 
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